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Background. Pentavalent antimony is the agent recommended for treatment of cutaneous leishmaniasis (CL).
Its use is problematic, because it is expensive and because of the potential for drug-associated adverse effects during
a lengthy and painful treatment course.
Methods. We tested the efficacy of thermotherapy for the treatment of CL due to Leishmania tropica in a
randomized, controlled trial in Kabul, Afghanistan. We enrolled 401 patients with a single CL lesion and admin-
istered thermotherapy using radio-frequency waves (1 treatment of 1 consecutive application at 50C for 30 s)
or sodium stibogluconate (SSG), administered either intralesionally (a total of 5 injections of 2–5 mL every 5–7
days, depending on lesion size) or intramuscularly (20 mg/kg daily for 21 days).
Results. Cure, defined as complete reepithelialization at 100 days after treatment initiation, was observed in
75 (69.4%) of 108 patients who received thermotherapy, 70 (75.3%) of 93 patients who received intralesional SSG,
and 26 (44.8%) of 58 patients who received intramuscular SSG. The OR for cure with thermotherapy was 2.80
(95% confidence interval [CI], 1.45–5.41), compared with intramuscular SSG treatment ( ). No statisticallyPp .002
significant difference was observed in the odds of cure in comparison of intralesional SSG and thermotherapy
treatments. The OR for cure with intralesional SSG treatment was 3.75 (95% CI, 1.86–7.54), compared with
intramuscular SSG treatment ( ). The time to cure was significantly shorter in the thermotherapy groupP ! .001
(median, 53 days) than in the intralesional SSG or intramuscularly SSG group (median, 75 days and 1100 days,
respectively; ).Pp .003
Conclusions. Thermotherapy is an effective, comparatively well-tolerated, and rapid treatment for CL, and it
should be considered as an alternative to antimony treatment.
World-wide, the largest focus of cutaneous leishmani-
asis (CL) is in Kabul, Afghanistan, where Leishmania
tropica is anthroponotically transmitted by the sand fly
Phlebotomus sergenti and where the estimated annual
case load has been 67,500–200,000 patients during the
past decade [1–3]. Because of limited resources avail-
able during and after the Afghan civil war, the treatment
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of patients with CL by the Afghan Ministry of Health
and by nongovernmental organizations is the only strat-
egy to control the epidemic.
Pentavalent antimonials—namely, sodium stibo-
gluconate (SSG) and meglumine antimoniate—are the
mainstay of anti-leishmanial therapy [4–6]. A leish-
maniasis vaccine does not exist [7]. In countries where
leishmaniasis is endemic, antimonials are typically ad-
ministered intramuscularly (at a dosage of 20 mg/kg/
day for 20–28 days) or intralesionally (at a dosage
dependent on the lesion size) [4, 5]. However, anti-
monials can have serious (usually reversible) adverse
effects (e.g., pancreatitis, hepatotoxicity, and cardiotox-
icity) when given intramuscularly [4,5], and they are
expensive [8]. Moreover, the invasiveness of the stan-
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dard procedure—a lengthy course of painful inoculations—
often leads patients to default on their full treatment course.
Low compliance appears to be the principal reason behind the
emergence of drug-resistant parasite strains, especially in areas
where there is anthroponotic leishmaniasis; for example, in
India, Sudan and Nepal [9]. Hence, research is focusing on the
development of alternative treatments that use different dosage
schedules, drugs, or methods of treatment [6].
Surprisingly, despite its regional importance, there is a dearth
of clinical data on CL caused by L. tropica, and there are only
limited data on natural or treatment-induced cure rates [10].
We evaluated the efficacy of thermotherapy as treatment for
CL due to L. tropica in Kabul and compared it with standard
intramuscular and intralesional SSG treatment in a controlled,
randomized trial.
METHODS
Study location and participants. The study was carried out
at the HealthNet International Khair Khana clinic in Kabul,
Afghanistan. This clinic has been operational since 1995 and
is the main leishmaniasis treatment center in Kabul [2, 3], with
4751 new and 25,783 follow-up patients treated in 2003. Eligible
patients were those who attended the clinic for leishmaniasis
treatment and who had only 1 suspected CL lesion. Inclusion
criteria were age of 15 years; the presence of a single, parasi-
tologically confirmed CL lesion; and no prior history of disease
and/or antimonial treatment. Exclusion criteria were the pres-
ence of a CL lesion located on or immediately adjacent to the
nose, lips, or eyes; pregnancy; breast-feeding; major surgery in
the previous 3 months; presence of any uncontrolled medical
condition; and anticipated unavailability for follow-up. Most
patients were current Kabul residents.
Study design and procedures. The study was a randomized,
controlled trial. There was no placebo group, because this
would have been unethical due to the severity of CL that L.
tropica causes and the social stigma associated with the disease
[2]. The London School of Hygiene and Tropical Medicine
Ethics Committee and the Afghan Ministry of Health approved
the study protocol and the consent form. According to
HealthNet International policy, all medical services provided
during the study were free of charge.
To detect a 20% difference in the cure rate between the SSG
and thermotherapy groups, assuming an 80% cure rate in the
SSG groups [4–6], with a 90% power and a 5% 2-sided type
I error, 98 subjects were needed in each group. To compensate
for anticipated loss to follow-up, 40% more patients were en-
rolled in each group. Eligible patients coming to the clinic for
treatment were briefed about the study, its aims, and the pro-
tocol. Patients were enrolled in the study after written consent
had been given. Patients then proceeded to pick 1 of 3 identical
cardboard pieces out of a hat (the cardboard had been labeled
with different treatment codes on one of its sides, the codes
being nonvisible to the patient). After patients were randomly
assigned to receive a treatment, the cardboard piece picked was
returned to the hat. The assigned treatments were as follows:
(1) intralesional administration of generic SSG (Albert David
Ltd., Calcutta, India), 5 injections of 2–5 mL (depending on
lesion size) every 5–7 days for a total of up to 29 days; (2)
daily intramuscular administration of SSG 20 mg/kg (up to a
maximum daily dose of 850 mg) for 21 days; and (3) a single
thermotherapy treatment (1 consecutive application of 50C
for 30 s, depending on lesion size).
Both SSG regimens are standard World Health Organization–
recommended treatment for CL in Afghanistan [11]. For in-
tralesional treatment, SSG was infiltrated around the lesion
until complete blanching of the lesion and its margin was ob-
tained [11]. For thermotherapy, the lesion and a 15–20-mm
border of healthy skin around the lesion were cleaned with
stabilized 0.1% chlorine dioxide solution, anesthetized with 1%
lidocaine HCl, and moistened with sterile saline solution; then
heat was applied locally with a portable, battery-operated, lo-
calized current field radio-frequency generator (ThermoMed
1.8; Thermosurgery Technologies), according to the manufac-
turer’s instructions. The generator has received 501K clearance
by the US Food and Drug Administration for CL treatment.
It produces a 6.78-mHz frequency, applied with a handset that
includes an applicator gauge with 2 electrodes that are placed
onto the diseased skin. The area between the electrodes covers
49–73 mm2, depending on the applicator gauge size used; there-
fore, several thermotherapy applications may be required to
cover a lesion. Once treatment begins, the temperature is mea-
sured by a thermistor embedded in one of the electrodes, en-
suring that the applied temperature remains constant. The ap-
plied radio frequencies excite the tissue molecules, producing
heat that evenly penetrates the upper dermis, exposing Leish-
mania amastigotes to high temperature without injuring the
healthy underlying tissue. After all treatments, a chlorine di-
oxide gel was applied to lesions, and lesions were covered with
gauze to prevent secondary infections.
Before the first treatment, all patients received a full physical
examination. The location and duration (prior to treatment)
of the lesion were recorded; its diameter was measured with a
caliper. The status of each lesion was evaluated during 4 patient
follow-up visits; the trial end point was 100 days after start of
therapy. Lesions with a secondary bacterial infection before,
during, or after treatment were treated with topical antibiotics.
If systemic treatment was required, patients received treatment
with an antibiotic that has no activity against Leishmania (e.g.,
erythromycin). The occurrence of adverse effects was evaluated
blindly by means of patient interviews and physical examina-
tions during follow-up visits.
Treatment efficacy was measured by the percentage of pa-
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Figure 1. Flow chart summarizing the enrollment and randomization of patients in a trial of thermotherapy for cutaneous leishmaniasis and listing
reasons for exclusion or withdrawal from the study. All values are no. of patients.
tients cured at 100 days after treatment initiation and by time
to cure. Cure was defined as the complete reepithelialization
of the CL lesion, with no evidence of papules, inflammation,
or induration. Patients that did not experience cure after 100
days were offered intralesional or intramuscular SSG, as
appropriate.
Parasitological studies. Parasitological confirmation of CL
was by microscopic examination in Kabul and parasite iden-
tification by PCR at Leeds University (Leeds, United Kingdom).
Microscopic examination was performed blindly. Scrapings
from the lesion edge were smeared onto a slide, and the slide
was dried, fixed with methanol, Giemsa-stained, and examined
under the microscope at 100 magnification for presence of
Leishmania amastigotes. For PCR, lesion scrapings were pre-
served in ethanol at 20C prior to DNA extraction using a
QIAamp DNA mini kit (Qiagen). Samples were amplified in a
nested PCR with Leishmania-specific kinetoplast minicircle
primers, under conditions published elsewhere [12]. This pro-
tocol differentiates between the major Leishmania species in
Central Asia, namely L. tropica, Leishmania major, and Leish-
mania infantum. Each PCR included appropriate negative and
positive controls. To evaluate sample degradation or PCR in-
hibition, sample DNA was also amplified for a 740-bp fragment
of the human TNFB gene [13].
Statistical analysis. All patient data were entered into Excel
software (Microsoft). A x2 test was used to test for significance
( ) between proportions (e.g., sex and loss to follow-up).P ! .05
All other analyses were done with Stata software, version 6.0
(Stata). A Kruskal-Wallis test was used to test for significance
between pretrial characteristics (e.g., age, body weight, lesion
size, and lesion duration) of treatment groups. The effects of
the treatments on the proportion of patients cured by 100 days
were tested by logistic regression. The analyses incorporated
the effect of explanatory variables (discussed above) and treat-
ment type. The significance of each variable was tested by back-
wards deletion; that is, by observation of whether these variables
explained a significant ( ) proportion of the devianceP ! .05
remaining after removal from the model. Variables were re-
moved from the models in order of least significance until only
significant variables (those with ) were retained in theP ! .05
minimum adequate model. The Kaplan-Meier method was
used for the time-to-healing analysis; to compare the healing
curves for the 3 treatment types, the log-rank test was used.
RESULTS
A total of 431 patients were enrolled in the study between
January and September 2003. After random treatment alloca-
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Table 1. Demographic and clinical characteristics of patients before treatment for cutaneous leishmaniasis.
Variable All patients
Intralesional
SSG group
Intramuscular
SSG group
Thermotherapy
group Pa
No. of patients 401 146 117 138
Sex, no. male/female 200/201 67/79 63/54 70/68
Age, median years (IQR) 13 (10–20) 13 (8.25–22) 13 (10–22) 14 (10–20) .75
Body weight, median kg (IQR) 39 (24–51) 36 (22–50) 38.5 (26–51.25) 40 (24–51) .70
Lesion diameter, median mm (IQR) 12 (7–20) 12.75 (7–20) 13.75 (8–22.5) 10.25 (7–20) .11
Lesion duration, median months (IQR) 6 (3–7) 6 (3–7) 5.5 (3–7) 6 (3.75–8) .19
NOTE IQR, interquartile range; SSG, sodium stibogluconate.
a A Kruskal-Wallis rank test was used to compare difference in pretreatment patient characteristics between treatment groups.
Table 2. Rates of loss to follow-up of patients in the trial.
Period,
treatment group
OR (95% CI)
Thermotherapy
group
Intralesional
SSG group
During treatment
Intramuscular SSG … 1.89 (1.06–3.38)a
Intralesional SSG … …
After the end of treatment
Intramuscular SSG 0.93 (0.44–1.97) 1.34 (0.59–3.05)
Intralesional SSG 0.70 (0.35–1.39) …
Throughout the study
Intramuscular SSG 3.48 (1.94–6.24)b 1.78 (1.05–3.03)a
Intralesional SSG 1.97 (1.13–3.47)a …
NOTE. ORs were estimated using the x2 test using data shown in figure
1. Excluded from the analyses are patients who withdrew from the study
because of the adverse effects of treatment. SSG, sodium stibogluconate.
a Not significant; .P ! .05
b Not significant; .P ! .001
tion, 30 patients decided to withdraw from the study (figure
1); 146 patients received intralesional SSG, 117 received intra-
muscular SSG, and 138 received thermotherapy treatment.
Baseline patient characteristics. All patients had lesions
parasitologically confirmed by microscopy. For a subset of 39
patients, lesion scrapings were obtained for PCR-based parasite
identification. All samples yielded amplification products for
the human TNFB gene fragment. Of these 39 samples, 27 (69%)
were PCR-positive for Leishmania DNA; for all 27, L. tropica
was identified. Demographic and clinical characteristics of pa-
tients are presented in table 1. No statistically significant dif-
ferences were observed between treatment groups with respect
to sex, age, body weight, lesion size, or lesion duration. The
lesions were primarily located on the face (43.4% of patients),
as well as on the hands (38.2%), legs (15.9%), and arms (2.4%).
The median times of follow-up visits for patients who com-
pleted the trial were day 13, day 21, day 49, and day 85, for
the first, second, third, and fourth visit, respectively.
Efficacy. A total of 259 patients (63.8%) completed treat-
ment and completed the 4 visits and 100 days of follow-up.
Of these 259 patients, 108 were treated with thermotherapy, 93
were treated with intralesional SSG, and 58 were treated with
intramuscular SSG (figure 1). In the intramuscular SSG group,
27 patients (47%) had their SSG dose limited by the protocol
ceiling of 850 mg/day. Thermotherapy-treated patients were
shown to be least likely to be lost to follow-up either during
or after the end of treatment (table 2).
Complete cure by 100 days was observed in 69.4% of patients
treated with thermotherapy, 75.3% of patients treated with in-
tralesional SSG, and 44.8% of patients treated with intramus-
cular SSG (table 3). None of the patients with complete healing
had relapse during the 100 days of the study. No statistically
significant association was shown between age, sex, body
weight, lesion size, lesion location or lesion duration and trial
outcome. The OR for cure with thermotherapy was 2.80 (95%
CI, 1.45–5.41), compared with intramuscular SSG treatment
( ). No statistically significant difference was observedPp .002
between the odds of cure with intralesional SSG or thermo-
therapy treatment (OR, 1.34; 95% CI, 0.72–2.50; ).Pp .359
The OR for cure with intralesional SSG treatment was 3.75
(95% CI, 1.86–7.54), compared with intramuscular SSG treat-
ment ( ). An intention-to-treat analysis of the data (i.e.,P ! .001
including the patients lost to follow-up, who were considered
to have had treatment failure) yielded similar results for the
comparison of the odds of cure for the different treatments
(table 3).
According to the Kaplan-Meier survival analysis (which an-
alyzes all available data, including those for patients who
dropped out of the study during treatment), the time to cure
was significantly shorter for patients treated with thermother-
apy (median, 53 days) than for those who were treated with
intralesional or intramuscular SSG (medians, 75 days and 1100
days, respectively; , by the log-rank test) (figure 2).Pp .003
Secondary infections were noted in 8 patients treated with
thermotherapy (2 before and 6 after treatment), in 5 patients
treated with intralesionally SSG (2 before and 3 after start of
treatment), and in 2 patients treated with intramuscular SSG
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Table 3. Cure rates and odds of cure under different assumptions for the 3 treatment groups at the end of the trial.
Analytical
assumptiona
Proportion (%) of patients
with cure at 100 days OR (95% CI)
IL SSG
group
IM SSG
group
TH
group
IL SSG
vs. TH
IL SSG
vs. IM SSG
IM SSG
vs. TH
Per protocol 70/93 (75.3) 26/58 (44.8) 75/108 (69.4) … … …
ITT 70/146 (47.9) 26/117 (22.2) 75/138 (54.3) 0.77 (0.47–1.27) 3.22 (1.81–5.77)b 0.24 (0.13–0.43)b
ITT var 105/146 (71.9) 70/117 (59.8) 75/138 (54.3) 2.15 (1.28–3.63)c 1.72 (0.99–2.98)d 1.25 (0.74–2.13)
NOTE Differences between per-protocol cure rates were analyzed using logistic regression (see Methods). IL, intralesional; IM, intramuscular;
ITT, intention to treat; SSG, sodium stibogluconate; TH, thermotherapy.
a Per protocol: analysis excluding patients that were lost to follow-up. ITT: analysis including patients lost to follow-up throughout the study,
who were considered to have experienced treatment failure. ITT var: analysis including patients lost to follow-up during treatment, who were
considered to have experienced cure, and including patients lost to follow-up after treatment completion, who were considered to have
experienced treatment failure.
b ; pairwise comparison of ITT cure rates was done with a x2 test of proportions, with ORs given in the table.P ! .001
c .P ! .01
d .P ! .05
Figure 2. Survival analysis of time to healing of cutaneous leishmaniasis lesions, with data on the no. of patients enrolled in the trial at baseline
and 4 other time points. IL, intralesional; IM, intramuscular; SSG, sodium stibogluconate; TH, thermotherapy.
(1 before and 1 after start of treatment), but the differences
were not statistically significant. All secondary infections re-
solved with antibiotic treatment. Excluded from the study after
treatment initiation were 2 patients treated with intralesional
SSG, because of bradycardia and an undefined local reaction
to the treatment; and 3 patients treated with intramuscular SSG,
because of bradycardia, tachycardia, and palpitation. In the
thermotherapy-treated group, the original CL ulcer often in-
creased in size immediately after and up to 2 weeks after treat-
ment, with patients experiencing superficial second-degree
burns where the electrodes were applied; thereafter, the lesion
closed rapidly (figure 2). This observation may explain the low
rate of follow-up among thermotherapy-treated patients in the
first 2 weeks after treatment; 25 (83%) of the 30 patients lost
to follow-up in the thermotherapy group were lost in the first
2 weeks. Patients may have become disheartened and unwilling
to seek further medical advice when lesions became bigger.
Though evaluation of scarring was not performed blindly, nei-
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ther the examining clinician nor patients noted a visible dif-
ference in the scarring between patient groups after successful
treatment.
DISCUSSION
We demonstrate that a single treatment with accurately mea-
sured localized heat is as effective as the administration of
intralesional SSG and more effective than the administration
of intramuscular SSG for the treatment of CL due to L. tropica.
The time to cure was shown to be shorter with thermotherapy
than with SSG regimens in a Kaplan-Meier analysis of data for
all study patients. We observed no significant effect of patient
characteristics on the cure rate.
Because of the postconflict situation in Afghanistan, enroll-
ment of patients was continuous throughout the study period.
The reason the intramuscular SSG treatment group was smaller
was that 27 patients who had been randomized to receive in-
tramuscular SSG treatment refused to give consent (figure 1).
Due to the social stigma associated with the disease, Kabul
residents are very knowledgeable about leishmaniasis. They
know that intramuscular SSG injections are painful and are
usually given to patients with multiple lesions or lesions on
sites where intralesional SSG administration will be difficult.
These patients requested intralesional SSG or thermotherapy
treatment and were excluded from the trial and given the treat-
ment they requested. Further proof of patients’ low acceptance
of intramuscular SSG treatment was that the number of patients
lost to follow-up during treatment was significantly greater in
the intramuscular SSG group than in the intralesional SSG
group ( ), but it was not significantly different after theP ! .05
end of treatment ( ) (figure 1 and table 2). Though thePp .58
number of patients lost to follow-up after the end of treatment
was not significantly different between treatment groups
( ) (figure 1), one caveat of our study is that we cannotPp .54
exclude the possibility that patients dropped out during treat-
ment because lesions were healing and, knowing that they had
to face the remaining SSG injections, they did not want to
attend further treatment visits. If one assumes that patients lost
to follow-up during treatment experienced cure, the cure rate
among patients treated with intralesional SSG would be sig-
nificantly larger than that for patients treated with intramus-
cular SSG or with thermotherapy; the cure rates in the latter
2 groups would not differ significantly (table 3).
Laboratory studies showed that Leishmania parasites do not
readily multiply in macrophages at temperatures 139C in vitro
[14, 15]. These observations led to studies investigating the
efficacy of thermotherapy treatment of CL with hot-water baths
[16], infrared light [17], direct-current electrical stimulation
[18], ultrasound [19], and laser light [20–23]. Specifically, 3
studies suggested that thermotherapy with radio-frequency
waves could be effective for CL treatment. In a placebo-con-
trolled trial, thermotherapy (3 treatments of 50C for 30 s at
7-day intervals) was as effective as antimony therapy (meglu-
mine antimoniate, 850 mg/day for 15 days) in treating L. bra-
ziliensis and L. mexicana infection [24]. Cure rates were iden-
tical—73% (16 of 22 patients), in each treatment group,
compared with 27% (6 of 22 patients) in the placebo control
group—13 weeks after treatment initiation [24]. In a second,
uncontrolled study of thermotherapy (a single treatment of
50C for 30 s) in L. mexicana–infected patients, cure rates of
95% (116 of 122 patients) and 90% (172 of 191 patients) were
observed 4 and 8 weeks after treatment, respectively [25]. In a
case report, a Sudanese patient with multiple L. tropica lesions
was cured 6 months after receiving thermotherapy (a single
treatment of 50C for 30 s) [26].
However, it is difficult to draw conclusions from these stud-
ies. First, they are case studies or include small numbers of
patients that preclude in-depth statistical analyses [16, 17, 19,
24, 26]. Second, some followed an undefined study protocol
(e.g., they lacked either placebo or control treatment groups)
[19, 25, 26]; one study had a short follow-up period that could
have excluded relapses [25] and another had a long follow-up
period that could have included cases of self-cure [26]. Third,
one study included patient groups that were treated with sub-
optimal durations of antimony treatment (i.e., !20–28 treat-
ment days) [24]. Fourth, one study included patients infected
with different or unknown Leishmania species [24].
There are many reports of successful administration of in-
tralesional antimony to cure Old World CL [4, 5, 27], but only
one study in Saudi Arabia compared intramuscular versus in-
tralesional administration of antimony [28]; cure rates were
68% and 73%, respectively, at 30 days after treatment (the
difference was not statistically significant). Therefore, to our
knowledge, our study is the first that shows that the intrale-
sional route of SSG administration is more effective than the
intramuscular route for treatment of Old World CL. This has
practical relevance in terms of drug management because, on
average, 10 times less drug is used when treating patients in-
tralesionally instead of intramuscularly (R.R., unpublished
data). Also, as observed here, patient compliance with intra-
lesional treatment is better, because fewer clinic visits and in-
jections are required. Surprisingly, comparable reported data
on cure rates for the treatment of confirmed L. tropica infection
with antimony are scarce: there is a single study reporting a
76% cure rate 10 weeks after intralesional meglumine anti-
moniate administration [29].
Localized heat could be an alternative to antimony for the
treatment of CL and, in particular, would be very cost-effective
in those areas of endemicity where the number of cases of
Leishmania infection is high and focal (e.g., areas with anthro-
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ponotic foci of CL). Reliable data on the cost of leishmaniasis
treatment are difficult to obtain and depend on several factors
(e.g., whether treatment is given on an inpatient or an out-
patient basis and whether cheaper, generic SSG is used); the
cost per patient treated range from US$20 in Afghanistan (R.R.
and P. G. Coleman, unpublished data) to US$280 in Guatemala
[30] to 1US$5500 in the United States (N. Aronson, personal
communication). The retail price of the thermotherapy device
used in the present study is US$23,450. There are 2 main ad-
vantages to the tested thermotherapy protocol, compared with
antimony treatment: (1) patient compliance rates are improved
because of the lack of potentially serious adverse effects of
treatment, because treatment is administered nonparenterally,
and because the treatment schedule is shorter (i.e., 1 day, com-
pared with 5–21 injection-days for antimony); and (2) the
shorter administration schedule also increases the patient turn-
over rate, a prerequisite for controlling the patient case load
and, hence, disease transmission. The tested thermotherapy
method uses a handheld device and limited additional medical
equipment, making it suitable for field conditions in areas with
rudimentary medical infrastructure; the device, however, needs
a power source to recharge the battery. Though we tested the
efficacy of thermotherapy on patients with single CL lesions
only, patients with multiple lesions could be treated in the same
way. Patients with CL lesions adjacent to the eyes and lips will
still have to be treated intramuscularly with SSG. Also, L. tropica
is one of the more temperature-resistant Leishmania species
[14, 15]. One would expect the thermotherapy method we
tested to be more effective against less temperature-resistant
Leishmania species; this awaits confirmation, for example for
L. major.
Ultimately, the decision to use thermotherapy will depend
on clinical factors (e.g., the location, size, and number of
lesions, and the patient’s responsiveness to antimony therapy)
and patient management factors (e.g., patients’ availability for
follow-up and the total treatment time per patient). In con-
clusion, thermotherapy with the tested device proved to be
effective, safe, and relatively noninvasive for treating patients
with CL in the current postconflict context of Kabul,
Afghanistan.
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